Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

NCT07398326 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT07398326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07398326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Lead sponsor
Shanghai Changzheng Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 24, 2026
Completion date
December 31, 2028
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer